CardioMetaboliQ Test

The CardioMetaboliQ Dried Blood Spot Test evaluates liver, metabolic, and cardiovascular physiology through an integrated systems lens. With 93.2% of U.S. adults showing suboptimal cardiometabolic health (O’Hearn 2022), the CardioMetaboliQ test is specifically designed to provide early visibility and enhance reversibility.

CMiQ translates biomarkers and anthropometrics into five focused domain scores that reveal hidden patterns across adiposity, vascular health, inflammation, glycemic control, and liver-associated dysfunction, giving clinicians rapid clarity and targeted action steps. Unlike conventional panels, it also includes the validated Fatty Liver Index, which detects early MASLD often missed by ALT/AST.

By highlighting root physiologic strain before damage becomes irreversible, CMiQ helps guide precise, coordinated intervention strategies.

ThyroMetaboliQ Test

The ThyroMetaboliQ Dried Blood Spot Test combines a full thyroid panel (TSH, fT3, fT4, TPO abs) with the CardioMetaboliQ panel. This integrated systems perspective can help reveal dysfunction missed by standard thyroid-only panels. Specifically designed for patients who may appear “normal” on standard thyroid labs while knowing something feels “off”.

TMiQ assesses metabolic factors such as insulin resistance, inflammation and fatty liver that may be impairing hormone activation and effectiveness rather than gland output. The TMiQ test converts thyroid and cardiometabolic biomarkers into seven domain scores that expose these often-hidden patterns and guide targeted intervention. As with all CMiQHealth panels, TMiQ includes the Fatty Liver Index to detect hepatic constraints on thyroid function. By identifying a potential metabolic “brake” on thyroid physiology, TMiQ helps clinicians visualize and address root cause and restore effective hormone signaling rather than relying on thyroid hormone replacement therapy.

EndoMetaboliQ Test

For Pre/Peri-Menopause

The EndoMetaboliQ Dried Blood Spot Test takes the thyroid and cardiometabolic insights of the TMiQ test and combines female and stress hormone status to yield a comprehensive overview of female physiology. Specifically designed for pre/peri- and early menopausal women, the EMTiQ panel can reveal elevated cardiometabolic risks and interconnected systemic effects that often rise as estrogen and progesterone levels decline.

Rather than viewing hormones in isolation, EMTiQ reveals how metabolic and hepatic factors such as insulin resistance and fatty liver disrupt hormone balance, thyroid activation, and symptom expression. The EMTiQ report translates biomarkers and anthropometrics (body metrics) into eight domain scores that expose hidden drivers of fatigue, weight change, vasomotor symptoms, mood shifts, and cognitive fog.

As with all panels, EMTiQ also includes the Fatty Liver Index to detect hepatic dysfunction early, helping clinicians target root cause and restore endocrine-metabolic balance instead of relying solely on hormone replacement.